Clinical Trial Update: Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating 177Lu-OPS201 with 68Ga-OPS202 imaging in somatostatin receptor 2–expressing cancers; study terminated with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Small Cell Lung Cancer

Drugs mentioned

• 177Lu-OPS201 (Lu-177 OPS201)
• 68Ga-OPS202

Snippet

Sponsor: Ipsen | Conditions: Small Cell Lung Cancer and Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-10-30